Literature DB >> 18413205

Increased urinary levels of CXCL5, CXCL8 and CXCL9 in patients with Type 2 diabetic nephropathy.

Mayumi Higurashi1, Yoshiyuki Ohya, Kensuke Joh, Masahiro Muraguchi, Motonobu Nishimura, Hiroyuki Terawaki, Kazuo Yagui, Naotake Hashimoto, Yasushi Saito, Kenichi Yamada.   

Abstract

CXC chemokines are particularly significant for leukocyte infiltration in inflammatory diseases. Recent reports have shown that inflammation is one of potential pathogenic mechanisms for diabetic nephropathy. However, information on inflammation related with CXC chemokines in human Type 2 diabetic nephropathy still remains scarce. We measured urinary and serum levels of three CXC chemokines, CXCL5, CXCL8 and CXCL9, in 45 Type 2 diabetic patients (DM), 42 primary renal disease (PRD) patients and 22 healthy controls by enzyme-linked immunosorbent assay. Urinary levels of CXCL5, CXCL8 and CXCL9 in DM were significantly elevated compared to those in controls (P<.0001, P<.01, P<.001; respectively). They increased consistent with urinary albumin excretion rate (UAER) and correlated with UAER in partial correlation analyses (r=0.41, P<.01; r=0.40, P<.01; r=0.45, P<.01; respectively). Urinary levels of CXCL5 in DM were significantly interrelated to HbA(1c) (r=0.42, P<.01). On the other hand, PRD showed significant increased levels of urinary CXCL8 and CXCL9 compared to controls (P<.001, P<.01; respectively), and so did PRD as UAER increased. However, there were no significant elevations of urinary levels of CXCL5 in PRD in spite of the increased UAER. We found significant associations of UAER in DM with diabetes duration, 1/serum creatinine, urinary CXCL5 (adjusted R(2)=0.67, P<.0001) or CXCL9 (adjusted R(2)=0.69, P<.0001) in a stepwise multiple regression analysis. These results suggest that these three CXC chemokines may be involved in the progression of human Type 2 diabetic nephropathy and that CXCL5 may be of use for telling diabetic nephropathy from primary renal diseases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18413205     DOI: 10.1016/j.jdiacomp.2007.12.001

Source DB:  PubMed          Journal:  J Diabetes Complications        ISSN: 1056-8727            Impact factor:   2.852


  14 in total

1.  Islet adaptation to obesity and insulin resistance in WNIN/GR-Ob rats.

Authors:  Himadri Singh; Sireesha Ganneru; Venkata Malakapalli; Maniprabha Chalasani; Giridharan Nappanveettil; Ramesh R Bhonde; Vijayalakshmi Venkatesan
Journal:  Islets       Date:  2014       Impact factor: 2.694

Review 2.  One Actor, Many Roles: Histopathologies Associated With APOL1 Genetic Variants.

Authors:  Jeffrey B Kopp; Avi Z Rosenberg
Journal:  Adv Anat Pathol       Date:  2019-05       Impact factor: 3.875

3.  Urinary chemokines CXCL9 and CXCL10 are noninvasive markers of renal allograft rejection and BK viral infection.

Authors:  J A Jackson; E J Kim; B Begley; J Cheeseman; T Harden; S D Perez; S Thomas; B Warshaw; A D Kirk
Journal:  Am J Transplant       Date:  2011-08-03       Impact factor: 8.086

4.  Increased serum CXCL1 and CXCL5 are linked to obesity, hyperglycemia, and impaired islet function.

Authors:  Craig S Nunemaker; H Grace Chung; Gretchen M Verrilli; Kathryn L Corbin; Aditi Upadhye; Poonam R Sharma
Journal:  J Endocrinol       Date:  2014-06-13       Impact factor: 4.286

5.  Overexpression of acetyl-coenzyme A carboxylase beta increases proinflammatory cytokines in cultured human renal proximal tubular epithelial cells.

Authors:  Masa-aki Kobayashi; Hirotaka Watada; Ryuzo Kawamori; Shiro Maeda
Journal:  Clin Exp Nephrol       Date:  2010-06-01       Impact factor: 2.801

6.  Temporal response characterization across individual multiomics profiles of prediabetic and diabetic subjects.

Authors:  Minzhang Zheng; Carlo Piermarocchi; George I Mias
Journal:  Sci Rep       Date:  2022-07-15       Impact factor: 4.996

7.  A crucial role for TNF-alpha in mediating neutrophil influx induced by endogenously generated or exogenous chemokines, KC/CXCL1 and LIX/CXCL5.

Authors:  S M Vieira; H P Lemos; R Grespan; M H Napimoga; D Dal-Secco; A Freitas; T M Cunha; W A Verri; D A Souza-Junior; M C Jamur; K S Fernandes; C Oliver; J S Silva; M M Teixeira; F Q Cunha
Journal:  Br J Pharmacol       Date:  2009-08-20       Impact factor: 8.739

8.  Serum amyloid A and inflammation in diabetic kidney disease and podocytes.

Authors:  Robert J Anderberg; Rick L Meek; Kelly L Hudkins; Sheryl K Cooney; Charles E Alpers; Renee C Leboeuf; Katherine R Tuttle
Journal:  Lab Invest       Date:  2014-12-22       Impact factor: 5.662

9.  Advanced glycation end products induce the apoptosis of and inflammation in mouse podocytes through CXCL9-mediated JAK2/STAT3 pathway activation.

Authors:  Jing Yu; Hao Wu; Zi-Yu Liu; Qi Zhu; Chang Shan; Ke-Qin Zhang
Journal:  Int J Mol Med       Date:  2017-08-11       Impact factor: 4.101

Review 10.  Pathogenic Pathways and Therapeutic Approaches Targeting Inflammation in Diabetic Nephropathy.

Authors:  Sandra Rayego-Mateos; José Luis Morgado-Pascual; Lucas Opazo-Ríos; Melania Guerrero-Hue; Cristina García-Caballero; Cristina Vázquez-Carballo; Sebastián Mas; Ana Belén Sanz; Carmen Herencia; Sergio Mezzano; Carmen Gómez-Guerrero; Juan Antonio Moreno; Jesús Egido
Journal:  Int J Mol Sci       Date:  2020-05-27       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.